View more job listings or post a job
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Post a job


[Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)

Speakers: Darrin Stuart, Scorpion Therapeutics; Jan Smith, Revolution Medicines; Shirley Liu, GV20 Therapeutics; Thierry Guillaudeux, CSO, Kineta; Sumith Kularatne, On Target Laboratories; Eric Blouin, Ipsos; Michael Pehl, Adcendo; Allen S. Yang, Summit Therapeutics; Samuel C. Blackman, Day One Biopharmaceuticals; Mark W. Frohlich, Indapta Therapeutics; Hequn Yin, Iovance Biotherapeutics; Jakob Dupont, Sofinnova Investments
Organizers: Toby Freedman (Synapsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Dawn Biopharma), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)
Date: 2024-08-14- 8/15/2024
Time: 8:30-13:15 Pacific Time
Registration fee: Free
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2024-08-13  (it will close sooner if the seating cap is reached)

About the Topic

This two-day symposium will discuss the latest advances in the discovery and development of cancer therapeutics from leading pharmaceutical companies and promising biotech companies.

Preliminary Agenda

Day 1, August 14

Time (PST) Topic Presenter(s)
8:30-9:00 am PBSS and BioScience Forum Welcome and Introduction, Symposium Overview, Agenda Review Shichang Miao, PhD, PBSS;  Joe Carlino, PhD, BioScienceForum
9:00-9:35 am Discovery and Development of Mutant-Selective PI3Kα Inhibitors Darrin Stuart, PhD, CSO, Scorpion Therapeutics
9:35-10:10 am Targeting Oncogenic RAS with Tri-Complex Inhibitors Jan Smith, PhD, CSO, Revolution Medicines
10:10-10:45 am Integrated Computation and Genomics for Cancer Target and Drug Discovery Shirley Liu, PhD, CEO, GV20 Therapeutics
10:45-11:00 am Break -
11:00-11:35 am Immunosuppressive Myeloid Cells – an Emerging Target in Cancer Immunotherapy Thierry Guillaudeux, PhD, CSO, Kineta
11:35 am-12:10 pm Targeted Drugs for Cancer Sumith Kularatne, PhD, Executive Vice President - R&D, On Target Laboratories
12:10-12:45 pm Oncology Drug Approvals: A Review of Recent Practice-Changing Approvals and a Look at the Near-Term Pipeline Eric Blouin, BM, Senior Vice Presiden -Oncology, Ipsos
12:45-1:15 pm Panel discussion All presenters

Day 2, August 15

Time (PST) Topic Presenter(s)
8:30-8:35 am Welcome and Introduction, Symposium Overview Dean Wilson, PhD, PBSS
8:35-9:10 am First-in-Class ADC for Hard-to-Treat Solid Tumor Cancers Michael Pehl, Dipl, CEO, Adcendo
9:10-9:45 am Development of Bispecific Antibodies for Cancer Allen S. Yang, MD, PhD, CMO, Summit Therapeutics
9:45-10:20 am From Concept to Proof: A New Model for Accelerating Pediatric Cancer Drug Development Samuel C. Blackman, MD, PhD, Founder and Head of R&D, Day One Biopharmaceuticals
10:20-10:35 am Break -
10:35-11:10 am Harnessing the Power of Naturally Occurring NK Cells to Fight Cancer & Autoimmune Disease Mark Frohlich, MD, CEO, Inadapta Therapeutics
11:10 am-11:45 pm Tumor Infiltrating Lymphocytes for Treating Solid Tumors Hequn Yin, PhD, SVP, Head of Research, Iovance Biotherapeutics
11:45-12:20 pm The Outlook for Innovation in Cancer Therapeutics: A VC Perspective Jakob Dupont, MD, MA, Executive Partner, Sofinnova Investments
12:20-12:50 pm Panel discussion All presenters

2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
©Pharmaceutical & BioScience Society, International; Last Modified: 7/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
Submit a Text Ad